Rigel to Present at Jefferies 2014 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2014
SOUTH SAN FRANCISCO, Calif., May 29, 2014 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the
company's chairman and chief executive officer, is scheduled to present a
company overview at the Jefferies 2014 Global Healthcare Conference in New
York City on Tuesday, June 3rd at 2:30 p.m. ET.
To access the live audio webcast or the subsequent archived recording, log on
to www.rigel.com. Please connect to Rigel's website several minutes prior to
the start of the live webcast to ensure adequate time for any software
download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc.is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the treatment of
inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's
pioneering research focuses on intracellular signaling pathways and related
targets that are critical to disease mechanisms. Rigel currently has five
product candidates in development: fostamatinib, an oral SYK inhibitor
expected to enter Phase 3 clinical trials for ITP in the second quarter of
2014 and a Phase 2 clinical trial for IgA nephropathy in the second half of
2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials
for dry eye; R118, an AMPK activator in Phase 1 development; and two oncology
product candidates in Phase 1 development with partners BerGenBio andDaiichi
Follow us on Twitter - @RigelPharma
Contact: Ryan Maynard
SOURCE Rigel Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.